

# To assess the effect of antibiotic eye drops (azithromycin) on the signs and symptoms of dry eyes (Meibomian gland dysfunction)

<b>Submission date</b> 03/06/2023	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 22/06/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 12/09/2024	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

One important factor affecting the quality of tears is the Meibomian glands' function. These are tiny glands located along the edges of the eyelids that produce an oily substance called meibum. This meibum helps to lubricate the surface of the eyes, prevent tear evaporation, and maintain the stability of the tear film. The modern lifestyle, which often involves spending time indoors with air conditioning and central heating, can have a noticeable impact on tear quality. Optometrists are well positioned to manage a condition called Meibomian gland dysfunction (MGD) within the community. In the UK, there has been an increase in Independent Prescribing Optometrists, with 500 registered with the General Optical Council. This allows practitioners to have more options for prescribing when treating MGD.

There are various treatment options available for MGD. However, patient compliance is a significant factor in determining the success of treatment, especially in chronic conditions. Research has shown that patients with long-term dry eye problems tend to have reduced compliance with lid hygiene. Finding a treatment that can break the cycle of dryness, inflammation, and keratinization of the Meibomian glands, and reduce the need for long-term management of MGD, could potentially improve the patient's quality of life and reduce the financial burden on the National Health Service, which currently supplies lubricants for ongoing treatment. The annual cost of managing dry eye disease was estimated to be around £570 per person per year in the UK.

Topical Azithromycin has been identified as a viable treatment option comparable to oral doxycycline. Research has found that it was as effective as doxycycline in restoring low levels of carotenoids typically found in MGD, thus improving tear film stability.

This study aims to analyze the effectiveness of topical azithromycin in reducing signs and symptoms of MGD, as well as the need for self-treatment methods, in a community Optometry practice in the UK.

Who can participate?

Patients with persistent Meibomian gland dysfunction (MGD) and previous treatment of lid hygiene, lubricants, heat & massage had been ineffective at relieving signs or symptoms.

What does the study involve?

The study involved patients to consent to the treatment and then to complete a post-treatment survey one year on.

What are the possible benefits and risks of participating?

Benefits, reduced symptoms and effect on lifestyle from MGD.

Risks are low, possible hypersensitivity to the drug.

Where is the study run from?

Jarvis Optometrist, a community Optometry practice (UK)

When is the study starting and how long is it expected to run for?

March 2026 to July 2020

Who is funding the study?

This study is self-funded, with research assistance from the College of Optometrists (UK)

Who is the main contact?

Ian Jarvis, [ian.jarvis2@nhs.scot](mailto:ian.jarvis2@nhs.scot)

## Contact information

**Type(s)**

Public

**Contact name**

Mr Ian Jarvis

**ORCID ID**

<https://orcid.org/0000-0002-7428-8233>

**Contact details**

24-26 Arbroath Road

Dundee

United Kingdom

DD4 6EP

+44 1382462236

[ian.jarvis2@nhs.scot](mailto:ian.jarvis2@nhs.scot)

**Type(s)**

Scientific

**Contact name**

Mr Ian Jarvis

**Contact details**

24-26 Arbroath Road  
Dundee  
United Kingdom  
DD4 6EP  
+44 1382462236  
ian.jarvis2@nhs.scot

**Type(s)**

Principal investigator

**Contact name**

Mr Ian Jarvis

**Contact details**

24-26 Arbroath Road  
Dundee  
United Kingdom  
DD4 6EP  
+44 1382462236  
ian.jarvis2@nhs.scot

**Additional identifiers****Clinical Trials Information System (CTIS)**

Nil known

**Integrated Research Application System (IRAS)**

269433

**Protocol serial number**

IRAS 269433

**Study information****Scientific Title**

The Topical Azithromycin Meibomian Gland Dysfunction Survey (TAMS): the effect of topical azithromycin on signs and symptoms of Meibomian gland dysfunction

**Acronym**

TAMS

**Study objectives**

The use of topical azithromycin reduces signs, symptoms and self-management of Meibomian gland dysfunction

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 01/10/2019, Wales Ethical Approval Committee 7 (Health and Care Research Wales Support and Delivery Centre, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, UK; +44 2922 940968; Wales.REC7@wales.nhs.uk), ref: 19/WA/0253

## **Study design**

Single centre interventional non randomized study

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Meibomian gland dysfunction

## **Interventions**

This study was conducted in a community Optometry practice over a 2 year period (2016-2018). Patients were invited to participate in the study, who had persistent Meibomian gland dysfunction (MGD) and previous treatment of lid hygiene, lubricants, heat & massage had been ineffective at relieving signs or symptoms. The first 40 suitable patients were invited to take part in the study, to minimise selection bias. There were no general health exclusions that needed to be applied. The treatment involved taking one drop of topical azithromycin, 15mg/g (Thea pharmaceuticals) twice daily for 2 weeks and then once a day for the following two weeks. After treatment, objective data was collected from the participant record

## **Intervention Type**

Drug

## **Phase**

Not Applicable

## **Drug/device/biological/vaccine name(s)**

Topical azithromycin, 15mg/g eye drops

## **Primary outcome(s)**

1. Meibomian gland dysfunction (MGD) measured using the Efron grading scale before and after treatment
2. Fluorescein tear break up time (FTBUT) measured after instillation of 1% Fluorescein (Bausch & Lomb minims) and measured in seconds, counted by the examiner, before and after treatment

## **Key secondary outcome(s)**

Long-term benefit of treatment on symptoms and self-treatment methods, by post-treatment survey one year on from treatment. In brief, the survey asked the participants how their management of MGD had changed, which dry eye symptoms they had pre- and post-treatment (sensitivity to light, gritty/ burning sensation and blurred vision). They were also asked to what extent their symptoms affected their lifestyle, (reading, night driving, computer use and watching television) and how they were affected by environmental conditions (windy, dry and air-conditioned environments). This used a combination of yes/no responses and a numerical grading of symptoms of 1-5, where 1= least affected and 5=most affected.

**Completion date**

27/10/2021

## Eligibility

**Key inclusion criteria**

This study was conducted in a community Optometry practice over a 2 year period (2016-2018). Patients were invited to participate in the study, who had persistent Meibomian gland dysfunction (MGD) and previous treatment of lid hygiene, lubricants, heat & massage had been ineffective at relieving signs or symptoms.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

39 years

**Upper age limit**

75 years

**Sex**

All

**Total final enrolment**

31

**Key exclusion criteria**

1. No Meibomian gland dysfunction
2. Managed Meibomian gland dysfunction

**Date of first enrolment**

02/10/2019

**Date of final enrolment**

13/01/2020

## Locations

**Countries of recruitment**

United Kingdom

Scotland

**Study participating centre**  
**Jarvis Optometrist**  
24-26 Arbroath Road  
Dundee  
United Kingdom  
DD4 6EP

## Sponsor information

**Organisation**  
University of Dundee

**ROR**  
<https://ror.org/03h2bxq36>

## Funder(s)

**Funder type**  
University/education

**Funder Name**  
School of Nursing and Health Sciences, University of Dundee

**Alternative Name(s)**  
School of Nursing & Health Sciences, University of Dundee, School of Nursing & Health Sciences,  
School of Nursing and Health Sciences

**Funding Body Type**  
Private sector organisation

**Funding Body Subtype**  
Universities (academic only)

**Location**  
United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during the study will be available on request from Ian Jarvis: [ian.jarvis2@nhs.scot](mailto:ian.jarvis2@nhs.scot)

## IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		11/05/2024	12/09/2024	Yes	No
<a href="#">Participant information sheet</a>	version 1.1	19/09/2019	16/06/2023	No	Yes
<a href="#">Protocol file</a>	version 1	12/05/2019	16/06/2023	No	No